Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
0.916
-0.005 (-0.59%)
At close: Dec 20, 2024, 4:00 PM
0.958
+0.042 (4.64%)
After-hours: Dec 20, 2024, 6:36 PM EST
Seres Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 126.33 | 126.33 | 7.13 | 144.93 | 33.22 | 34.51 | Upgrade
|
| Revenue Growth (YoY) | 12856.41% | 1672.24% | -95.08% | 336.33% | -3.74% | 22.07% | Upgrade
|
| Cost of Revenue | 138.93 | 145.86 | 172.92 | 141.89 | 90.57 | 80.14 | Upgrade
|
| Gross Profit | -12.61 | -19.54 | -165.79 | 3.04 | -57.36 | -45.64 | Upgrade
|
| Selling, General & Admin | 64.95 | 87.74 | 79.69 | 69.26 | 30.78 | 24.75 | Upgrade
|
| Research & Development | -35.87 | - | - | - | - | - | Upgrade
|
| Other Operating Expenses | 0.7 | 0.7 | 1 | -1.73 | - | - | Upgrade
|
| Operating Expenses | 29.78 | 88.45 | 80.7 | 67.53 | 30.78 | 24.75 | Upgrade
|
| Operating Income | -42.39 | -107.98 | -246.49 | -64.49 | -88.13 | -70.38 | Upgrade
|
| Interest Expense | -10.71 | -13.18 | -6.02 | -2.91 | -2.92 | -0.5 | Upgrade
|
| Interest & Investment Income | 5.5 | 7.3 | 3.06 | 2.87 | 0.95 | 1.03 | Upgrade
|
| Other Non Operating Income (Expenses) | -20.85 | -0.1 | -0.02 | -0.55 | 1.43 | 0.89 | Upgrade
|
| EBT Excluding Unusual Items | -68.45 | -113.96 | -249.47 | -65.08 | -88.68 | -68.96 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | - | -1.49 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.24 | -0.69 | -0.5 | -0.45 | 0.17 | Upgrade
|
| Pretax Income | -68.45 | -113.72 | -250.16 | -65.58 | -89.13 | -70.28 | Upgrade
|
| Net Income | -25.48 | -113.72 | -250.16 | -65.58 | -89.13 | -70.28 | Upgrade
|
| Net Income to Common | -25.48 | -113.72 | -250.16 | -65.58 | -89.13 | -70.28 | Upgrade
|
| Shares Outstanding (Basic) | 145 | 128 | 108 | 92 | 80 | 57 | Upgrade
|
| Shares Outstanding (Diluted) | 145 | 128 | 108 | 92 | 80 | 57 | Upgrade
|
| Shares Change (YoY) | 14.47% | 18.44% | 17.86% | 14.93% | 40.85% | 39.04% | Upgrade
|
| EPS (Basic) | -0.18 | -0.89 | -2.31 | -0.72 | -1.12 | -1.24 | Upgrade
|
| EPS (Diluted) | -0.18 | -0.89 | -2.31 | -0.72 | -1.12 | -1.24 | Upgrade
|
| Free Cash Flow | -158.39 | -125.33 | -238.64 | -2.88 | -94.2 | -77.52 | Upgrade
|
| Free Cash Flow Per Share | -1.09 | -0.98 | -2.21 | -0.03 | -1.18 | -1.37 | Upgrade
|
| Gross Margin | -9.98% | -15.46% | - | 2.09% | -172.68% | -132.26% | Upgrade
|
| Operating Margin | -33.56% | -85.48% | -3458.05% | -44.50% | -265.33% | -203.98% | Upgrade
|
| Profit Margin | -20.17% | -90.02% | -3509.50% | -45.25% | -268.33% | -203.68% | Upgrade
|
| Free Cash Flow Margin | -125.39% | -99.21% | -3347.88% | -1.99% | -283.61% | -224.67% | Upgrade
|
| EBITDA | -36.38 | -101.74 | -239.86 | -58.55 | -81.55 | -62.78 | Upgrade
|
| EBITDA Margin | -28.79% | -80.54% | - | -40.40% | -245.53% | -181.95% | Upgrade
|
| D&A For EBITDA | 6.02 | 6.24 | 6.63 | 5.95 | 6.58 | 7.6 | Upgrade
|
| EBIT | -42.39 | -107.98 | -246.49 | -64.49 | -88.13 | -70.38 | Upgrade
|
| EBIT Margin | -33.56% | -85.48% | - | -44.50% | -265.33% | -203.98% | Upgrade
|
| Revenue as Reported | 126.33 | 126.33 | 7.13 | 144.93 | 33.22 | 34.51 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.